Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $23.00 at Wells Fargo & Company

Bicara Therapeutics (NASDAQ:BCAX) had its price objective raised by Wells Fargo & Company from $16.00 to $23.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective would indicate a potential downside of 3.20% from the company’s previous close.

Several other equities research analysts also recently issued reports on BCAX. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Monday, July 6th. Guggenheim initiated coverage on Bicara Therapeutics in a research note on Monday, May 11th. They set a “buy” rating and a $42.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Bicara Therapeutics in a report on Wednesday, May 27th. The Goldman Sachs Group reaffirmed a “neutral” rating on shares of Bicara Therapeutics in a report on Wednesday. Finally, Morgan Stanley restated an “overweight” rating and issued a $39.00 price objective on shares of Bicara Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $32.09.

Bicara Therapeutics Price Performance

Shares of BCAX opened at $23.76 on Wednesday. Bicara Therapeutics has a 1 year low of $9.67 and a 1 year high of $30.99. The stock’s fifty day moving average price is $25.90 and its two-hundred day moving average price is $21.69. The firm has a market cap of $1.56 billion, a PE ratio of -8.55 and a beta of -0.75.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.82) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.82). Sell-side analysts anticipate that Bicara Therapeutics will post -3.42 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Claire Mazumdar sold 10,000 shares of the firm’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $28.42, for a total transaction of $284,200.00. Following the transaction, the chief executive officer directly owned 362,152 shares of the company’s stock, valued at approximately $10,292,359.84. This trade represents a 2.69% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 28,000 shares of the business’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $28.85, for a total value of $807,800.00. Following the completion of the sale, the chief financial officer directly owned 129,855 shares of the company’s stock, valued at approximately $3,746,316.75. This trade represents a 17.74% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 88,450 shares of company stock worth $2,366,675. Insiders own 13.80% of the company’s stock.

Institutional Trading of Bicara Therapeutics

A number of hedge funds have recently modified their holdings of BCAX. Mirae Asset Global Investments Co. Ltd. purchased a new position in Bicara Therapeutics during the fourth quarter valued at $45,000. Legal & General Group Plc increased its stake in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after purchasing an additional 1,233 shares in the last quarter. Larson Financial Group LLC increased its stake in Bicara Therapeutics by 1,015.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after purchasing an additional 3,595 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in Bicara Therapeutics by 419.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after buying an additional 3,866 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its stake in shares of Bicara Therapeutics by 385.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock worth $97,000 after buying an additional 4,585 shares in the last quarter.

Key Headlines Impacting Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: BTIG raises price target: BTIG Research increased its price target for Bicara from $28 to $39 and upgraded the stock to “buy,” implying substantial upside from recent trading levels. Benzinga report
• Positive Sentiment: Pivotal cancer trial remains on schedule: Wedbush said Bicara’s cancer study is on track to complete enrollment in 2026, supporting the company’s near-term clinical-development outlook. Wedbush cancer study report
• Positive Sentiment: Clinical progress highlighted: Bicara reported second-quarter progress, including advances in pivotal-trial enrollment. The update previously helped drive gains in the stock and reinforces expectations that the company is progressing toward important clinical milestones. Yahoo Finance trial-enrollment report
• Neutral Sentiment: Quarterly loss matched expectations: Bicara reported a second-quarter loss of $0.82 per share, in line with the analyst consensus estimate. The result provided no earnings surprise, while the company remains unprofitable and analysts expect a full-year loss. Bicara earnings report
• Negative Sentiment: Leadership transition adds execution uncertainty: Bicara announced strategic leadership changes as it moves into its next phase of execution and growth. Although management characterized the changes as part of the company’s evolution, investors may view the transition as an added risk while pivotal-trial execution remains central to the valuation. Bicara quarterly update and leadership transition

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.